SZShuyun Zhao

Shuyun Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuyun Zhao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pyroptosis in endometritis: Molecular mechanisms, pathogenic roles, and therapeutic opportunities

    by Yongyan Lu, Guangli Wang, Xueyu Qin, Guanyou Huang, Shuyun Zhao, Hen Luo


  • Open Access

    IGF‐1 Deficiency Serves as an Integrated Biomarker Pathogenic Driver and Predictor in Poor Ovarian Response

    by Zhu Hu, Yuanyuan Yu, Guanyou Huang, Jinnan Li, Chao Yang, Aizhuan Long, Jia Tang, Tengxiang Chen, Shuyun Zhao, Tuo Zhang

    Poor ovarian response (POR) constitutes a notable clinical challenge within the domain of assisted reproductive technology, primarily attributable to the lack of reliable biomarkers for precise diagnosis and treatment. This study reveals significantly reduced levels of insulin‐like growth factor 1 (IGF‐1) in the serum, follicular fluid (FF), and granulosa cells (GCs) of patients with POR in comparison to those exhibiting a normal ovarian response (NOR). Notably, FF IGF‐1 concentrations demonstrated significant positive correlations with crucial IVF outcomes, including the numbers of metaphase II (MII) oocytes, 2‐pronuclear zygotes, and high‐quality embryos. To establish causality, we employed complementary in vivo models: systemic insulin‐like growth factor binding protein acid labile subunit ( Igfals ) knockout mice and granulosa cell specific IGF‐1 receptor ( Igf‐1r ) knockout mice. These models collectively demonstrated that disruption of the IGF‐1 signaling axis impairs follicle‐stimulating hormone (FSH) responsiveness and arrests follicular development at the secondary stage, thereby recapitulating the core POR phenotype. Building on these mechanistic insights, we developed novel clinical prediction tools based on FF IGF‐1: a POR risk model [Area under the curve (AUC) = 0.914] and a pregnancy outcome nomogram (AUC = 0.893), both of which significantly outperform traditional ovarian reserve parameters (such as anti‐Müllerian hormone and antral follicle count). Decision curve analysis (DCA) further validated a substantial clinical net benefit. This study aids clinicians in the early identification of patients with POR and provides a theoretical foundation for timely intervention and adjustment of treatment strategies.

  • Open Access

    Prepared radix polygoni multiflori and emodin alleviate lipid droplet accumulation in nonalcoholic fatty liver disease through MAPK signaling pathway inhibition

    by Changyudong Huang, Yiqiong Zhang, Yongjie Xu, Sijia Wei, Tingting Yang, Shuang Wang, Chengcheng Li, Hairong Lin, Xing Li, Shuyun Zhao, et al.

    As one of the most common liver diseases, nonalcoholic fatty liver disease (NAFLD) affects almost one-quarter of the world’s population. Although the prevalence of NAFLD is continuously rising, effective medical treatments are still inadequate. Radix Polygoni Multiflori (RPM) is a traditional Chinese herbal medicine. As a processed product of RPM, prepared Radix Polygoni Multiflori (PRPM) has been reported to have antioxidant and anti-inflammatory effects. This study investigated whether PRPM treatment could significantly improve NAFLD. We used recent literature, the Herb database and the SwissADME database to isolate the active compounds of PRPM. The OMIM, DisGeNET and GeneCards databases were used to isolate NAFLD-related target genes, and GO functional enrichment and KEGG pathway enrichment analyses were conducted. Moreover, PRPM treatment in NAFLD model mice was evaluated. The results indicate that the target genes are mainly enriched in the AMPK and de novo lipogenesis signaling pathways and that PRPM treatment improves NAFLD disease in model mice. Here, we found the potential benefits of PRPM against NAFLD and demonstrated in vivo and in vitro that PRPM and its ingredient emodin downregulate phosphorylated P38/P38, phosphorylated ERK1/2 and genes related to de novo adipogenesis signaling pathways and reduce lipid droplet accumulation. In conclusion, our findings revealed a novel therapeutic role for PRPM in the treatment of NAFLD and metabolic inflammation.